الفهرس 
cover englishOnly 14 pages are availabe for public view
 |  | from | 193 |  |  |
| | | from | 193 | | |
Abstract
ALL is the most common Childhood Cancer, and Remarkable Improvements in Outcome Have Been Achieved. Certain Subgroups of Children With ALL Now Have a 95% Chance for Cure. Our Study Was Designed to Assess Survival of Childhood ALL at National Cancer Institute, Cairo, Egypy, Using ALL protocol adopted from SJCRH Total XV Protocol.Patients and Methods.We Reviewed the Medical Records of 264 Children 1–18 years of Age Who Were Diagnosed With ALL and Treated at Our institution from January 2007 through
December 2009. Disease characteristics and outcome were analyzed Results One hundred and sixty-nine (64%) were males. The median age at diagnosis was 6.0 years. One hundred and eighteen (44.6%) children were classified as low-risk, 132 50%) were standard-risk and 14 (5.3%) were high-risk. Fifty nine (22.5.5%) had T cell phenotype. Two hundred and twenty-six (85.6%) children were classified as having CNS I disease, 26 (9.8%) had CNS II, and 12 (4.5%) had CNS III. Induction failures were in nine patients (3.9%), two patients had persistence leukemia Thirty (11.4%) children died in induction, and 24 (9.1%) relapsed. The site of relapse in 11 (54.8%) patients was isolated BM. Eight (33.3%) patients relapsed in the CNS and four patients (1.5%) had BM and CNS relapses. One patient had in the extramedullary site (Leukemic infiltrate in the eye), no testicular relapse recorded. The estimated 3-year event free survival and overall survival were (74.6%) and
(81.0%), respectively, the median follow up period was 27.9 months. One hundred sixty four (62.1%) patients who remained in CCR. Overall abandonment of leukemia treatment rate was 17% in the study population Conclusion ALL protocol adopted from SJCRH Total XV treatment protocol was effective in improving ALL survival among patients at our institute, although the outcome Abstract remains lower than that in more developed countries Key words: Acute lymphoblastic leukemia, Relapse, Survival.